Decision Making in Proliferative Diabetic Retinopathy Treatment

Mary B. Kansora, Raquel Goldhardt

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations


Purpose of Review: The goal of this paper is to provide a comprehensive review of the recent advances in the management options for proliferative diabetic retinopathy. Recent Findings: For many years, cases of proliferative diabetic retinopathy (PDR) have been managed by pan retinal photocoagulation (PRP). The advent of anti-vascular endothelial growth factor (anti-VEGF) agents has changed the future of PDR management and has provided an alternative to PRP. Summary: Management of PDR requires the identification of high-risk characteristics for PDR and the decision regarding the most appropriate treatment modality. The risk to benefit ratio for each treatment modality must be considered in determining the appropriate choice between surgical intervention (PRP) versus medical intervention with anti-VEGF.

Original languageEnglish (US)
Pages (from-to)45-50
Number of pages6
JournalCurrent Ophthalmology Reports
Issue number1
StatePublished - Mar 15 2019


  • Aflibercept
  • Anti-VEGF
  • Bevacizumab
  • Intravitreal injection
  • Pan retinal photocoagulation
  • Proliferative diabetic retinopathy
  • Ranibizumab
  • Vascular endothelial growth factor

ASJC Scopus subject areas

  • Ophthalmology


Dive into the research topics of 'Decision Making in Proliferative Diabetic Retinopathy Treatment'. Together they form a unique fingerprint.

Cite this